Back to results
RecruitingPhase 3

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Infirmary Cancer Care ( Site 0001)

Mobile, Alabama, United States

+307 additional locations

Contact

Toll Free Number

1-888-577-8839Trialsites@msd.com
View on ClinicalTrials.gov
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) — TrialFind